Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Targovax ASA ( (GB:0RIS) ).
Circio Holding ASA has called an extraordinary general meeting for 12 January 2026 to seek shareholder approval for an 88%-secured rights issue of up to NOK 50 million, priced at NOK 1.00 per share, backed by substantial pre-subscriptions from major shareholders and an underwriting commitment. The company plans to use the net proceeds as its main funding source for the next year, after closing its previous financing facility with Atlas Capital Markets, enabling it to advance key pre-clinical milestones for its circVec platform, pursue business development including a feasibility study with a major global pharma partner, and potentially extend its cash runway into 2027 via attached warrants; the board is also asking for renewed share capital authorizations to support future equity issues and share-based incentive programs, underscoring an active capital markets strategy to sustain operations and retain key talent.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing circular RNA (circRNA) expression technology for gene and cell therapy. Its proprietary circVec platform is designed to deliver more durable and higher-level protein expression than conventional mRNA-based viral and non-viral vector systems, targeting applications in genetic medicine, cell therapy and chronic disease. The company also maintains a legacy immuno-oncology program, TG01, a therapeutic peptide vaccine targeting RAS-mutated cancers that is currently being evaluated in clinical trials in Norway and the USA.
Average Trading Volume: 5,446,487
Current Market Cap: NOK177.2M
Find detailed analytics on 0RIS stock on TipRanks’ Stock Analysis page.